Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Sep;39(9):2123–2127. doi: 10.1128/aac.39.9.2123

In vitro and in vivo activities of clinafloxacin, CI-990 (PD 131112), and PD 138312 versus enterococci.

M A Cohen 1, S L Yoder 1, M D Huband 1, G E Roland 1, C L Courtney 1
PMCID: PMC162893  PMID: 8540728

Abstract

Certain new fluoroquinolones have high activity against enterococci. Against Enterococcus faecalis (n = 18), MICs at which 90% of the isolates were inhibited were as follows (in micrograms per milliliter): clinafloxacin, 0.125; CI-990, 0.5; and PD 138312, 0.25 (compared with 1 microgram/ml for ciprofloxacin and 2 micrograms/ml for ofloxacin). Strains producing beta-lactamase or that were vancomycin resistant or resistant to high-level gentamicin were not quinolone cross-resistant. The drugs were bactericidal and were unaffected by 50% human serum. Oral efficacies (in milligrams per kilogram of body weight for 50% protective doses) in lethal mouse infections with quinolone-susceptible strains were 4.3 to 24 for clinafloxacin, 7.2 to 39 for CI-990, 7.2 to 76 for PD 138312, and 41 to > 100 for ciprofloxacin; when the drugs were given subcutaneously, the order was similar and values ranged from 1.1 to 12.5. Clinafloxacin, CI-990, and PD 138312 may have therapeutic potential in systemic enterococcal infections in humans.

Full Text

The Full Text of this article is available as a PDF (187.0 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barrett M. S., Jones R. N., Erwin M. E., Johnson D. M., Briggs B. M. Antimicrobial activity evaluations of two new quinolones, PD127391 (CI-960 and AM-1091) and PD131628. Diagn Microbiol Infect Dis. 1991 Sep-Oct;14(5):389–401. doi: 10.1016/0732-8893(91)90066-o. [DOI] [PubMed] [Google Scholar]
  2. Burney S., Landman D., Quale J. M. Activity of clinafloxacin against multidrug-resistant Enterococcus faecium. Antimicrob Agents Chemother. 1994 Jul;38(7):1668–1670. doi: 10.1128/aac.38.7.1668. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Domagala J. M., Heifetz C. L. In vitro antibacterial activities of PD 131628, a new 1,8-naphthyridine anti-infective agent. Antimicrob Agents Chemother. 1991 Jan;35(1):141–146. doi: 10.1128/aac.35.1.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cohen M. A., Huband M. D., Mailloux G. B., Yoder S. L., Roland G. E., Heifetz C. L. In vitro antibacterial activities of the fluoroquinolones PD 117596, PD 124816, and PD 127391. Diagn Microbiol Infect Dis. 1991 May-Jun;14(3):245–258. doi: 10.1016/0732-8893(91)90039-i. [DOI] [PubMed] [Google Scholar]
  5. Culotta E. Funding crunch hobbles antibiotic resistance research. Science. 1994 Apr 15;264(5157):362–363. doi: 10.1126/science.8153617. [DOI] [PubMed] [Google Scholar]
  6. Fuchs P. C., Barry A. L., Pfaller M. A., Allen S. D., Gerlach E. H. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother. 1991 Apr;35(4):764–766. doi: 10.1128/aac.35.4.764. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Huband M. D., Cohen M. A., Meservey M. A., Roland G. E., Yoder S. L., Dazer M. E., Domagala J. M. In vitro antibacterial activities of PD 138312 and PD 140248, new fluoronaphthyridines with outstanding gram-positive potency. Antimicrob Agents Chemother. 1993 Dec;37(12):2563–2570. doi: 10.1128/aac.37.12.2563. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kirby W. M., Regamey C. Pharmacokinetics of cefazolin compared with four other cephalosporins. J Infect Dis. 1973 Oct;128(Suppl):S341–S346. doi: 10.1093/infdis/128.supplement_2.s341. [DOI] [PubMed] [Google Scholar]
  9. Miranda A. G., Wanger A. R., Singh K. V., Murray B. E. Comparative in vitro activity of PD 127391, a new fluoroquinolone agent, against susceptible and resistant clinical isolates of gram-positive cocci. Antimicrob Agents Chemother. 1992 Jun;36(6):1325–1328. doi: 10.1128/aac.36.6.1325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Moellering R. C., Jr The Garrod Lecture. The enterococcus: a classic example of the impact of antimicrobial resistance on therapeutic options. J Antimicrob Chemother. 1991 Jul;28(1):1–12. doi: 10.1093/jac/28.1.1. [DOI] [PubMed] [Google Scholar]
  11. Murray B. E. Beta-lactamase-producing enterococci. Antimicrob Agents Chemother. 1992 Nov;36(11):2355–2359. doi: 10.1128/aac.36.11.2355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Schaberg D. R., Dillon W. I., Terpenning M. S., Robinson K. A., Bradley S. F., Kauffman C. A. Increasing resistance of enterococci to ciprofloxacin. Antimicrob Agents Chemother. 1992 Nov;36(11):2533–2535. doi: 10.1128/aac.36.11.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Shlaes D. M., Rice L. B. Bacterial resistance to the cyclic glycopeptides. Trends Microbiol. 1994 Oct;2(10):385–388. doi: 10.1016/0966-842x(94)90616-5. [DOI] [PubMed] [Google Scholar]
  14. Spera R. V., Jr, Farber B. F. Multiply-resistant Enterococcus faecium. The nosocomial pathogen of the 1990s. JAMA. 1992 Nov 11;268(18):2563–2564. [PubMed] [Google Scholar]
  15. Watanakunakorn C. Increasing prevalence of resistance to ampicillin, penicillin and vancomycin of enterococci isolated from blood cultures during 1990-1991. J Antimicrob Chemother. 1993 Feb;31(2):325–326. doi: 10.1093/jac/31.2.325. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES